Aspira Women's Health Inc.
Aspira Women's Health Inc. (AWHL): 3 pipeline candidates · ~17 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
17.4 months
D/E -1.82 · 5% dilution
Lead: Approved
3 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for Aspira Women's Health Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$23.7M
Cash
$1.3M
Quarterly Burn
$359K
Runway
17.4 mo
Revenue
$32K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in Aspira Women's Health Inc.'s pipeline?
Aspira Women's Health Inc. (AWHL) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aspira Women's Health Inc.'s lead drug candidate?
Aspira Women's Health Inc.'s most advanced tracked candidate is ova1 (Approved) for likelihood of malignancy in women with an ovarian adnexal mass.
What is Aspira Women's Health Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aspira Women's Health Inc. has approximately 17.4 months of cash runway.
What is Aspira Women's Health Inc.'s market capitalization?
Aspira Women's Health Inc.'s market capitalization is approximately $23.7M.
Who is the CEO of Aspira Women's Health Inc.?
Mr. Michael Buhle is the chief executive officer of Aspira Women's Health Inc. (AWHL).
Get the full picture on Aspira Women's Health Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.